Free Trial
NASDAQ:BMRA

Biomerica Q1 2025 Earnings Results & Report

Biomerica logo
$1.83 -0.06 (-3.17%)
As of 10/9/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biomerica reported Q1 2025 earnings on October 15, 2024. The company reported EPS of -$0.64, while revenue was $1.81 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date

Biomerica EPS Results

Actual EPS
-$0.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biomerica Revenue Results

Actual Revenue
$1.81 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Biomerica's next earnings date is estimated for Wednesday, October 21, 2026, based on past reporting schedules.

Conference Call Resources

Biomerica Q1 2025 Earnings FAQ

Biomerica (NASDAQ:BMRA) reported earnings of -$0.64 per share for Q1 2025. The report was announced on Tuesday, October 15, 2024.

Biomerica reported revenue of $1.81 million for Q1 2025.

Biomerica's next earnings date is estimated for Wednesday, October 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for Biomerica on the company's earnings history page.

Biomerica Earnings Headlines

Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
Biomerica Files $250 Million Mixed Shelf
See More Biomerica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomerica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomerica and other key companies, straight to your email.

About Biomerica

Biomerica (NASDAQ:BMRA) is a medical diagnostics company that develops and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. The company focuses on tests and related solutions intended to support more personalized treatment decisions.

Biomerica’s best-known product platform is inFoods, which uses blood-based testing to identify foods that may contribute to symptoms associated with gastrointestinal disorders. The company has emphasized inFoods IBS, a diagnostic-guided dietary management solution for people with irritable bowel syndrome, pairing test results with individualized food recommendations.

Biomerica also has developed and marketed diagnostic products for conditions including Helicobacter pylori infection, allergies and respiratory illnesses. Its products have been distributed through healthcare providers and commercial partners in the United States and select international markets. The company is headquartered in Irvine, California, and has been led by Chief Executive Officer Zackary Irani.

View Biomerica Profile